Sacituzumab govitecan is another ADC that targets Trop-2, an epithelial antigen expressed by HR-positive/HER2-negative breast cancer and TNBC that is linked to tumor progression and poor prognosis [18]. This evidence concerns the gene ERBB2 and neoplasm.